Fig. 1
From: Taletrectinib promotes pyroptosis in colorectal carcinoma via SRC/AKT/mTOR axis inhibition
Taletrectinib regulates colorectal cancer cell damage. (A) HCT116 cells treated with small molecule drugs from the Pyroptosis Compound Library, were subjected to a CCK8 assay to detect changes in the tumor cells inhibition rate. (B) CCK8 assay was used to determine the inhibition rate of HCT116 and LoVo cells treated with 17 selected drugs. (C) Five small molecules were used to treat CRC cells. CCK8 assay results showed that taletrectinib exerted the best effect on two types of cells. (D) Small molecule structure of taletrectinib. (E) Transcriptome sequencing of HCT116 and LoVo cells. A ROS1/NTRK fusion gene was not found in either cell line. (F) Results of the CCK-8 assay. HCT116 and LoVo cells were treated with taletrectinib at different concentrations for 24 h. *** P < 0.001.
